Leen Kawas built a biotechnology company that raised over $300 million from investors including Pfizer before it collapsed amid research fraud revelations. Kawas resigned as CEO of Athira Pharma in October 2021 after an internal investigation found she had systematically falsified images in her doctoral dissertation and at least four research papers. In January 2025, Athira Pharma agreed to pay $4,068,698 to settle False Claims Act allegations for failing to report the research misconduct to federal agencies between 2016 and 2021. Separately, Athira paid $10 million in February 2023 to settle securities fraud class action lawsuits filed in the U.S. District Court for the Western District of Washington. No criminal charges were filed against Kawas personally, but the combined $14 million in civil settlements, along with a stock collapse from $17 to under $1 per share and eventual company wind-down, represents one of the most significant research fraud cases in biotechnology.
The Founder and Her Company
Leen Kawas earned her PhD in neuroscience from Washington State University in 2012. Her dissertation and research papers claimed to show that a compound called dihexa had therapeutic effects on rats with brain damage. She co-founded M3 Biotechnology in 2013 to commercialize dihexa for Alzheimer’s treatment. The company raised $68 million from investors including Pfizer, entered multiple clinical trials, and in September 2020 went public as Athira Pharma at $17 per share, raising $238 million. The IPO valued the company at $622 million. Kawas served as CEO and owned 6.5 million shares worth over $110 million.
The Research Fraud
In October 2021, Athira’s board announced that an internal investigation found Kawas had altered images in her doctoral dissertation and at least four research papers written at Washington State University between 2008 and 2012. Research integrity consultants hired by the board found problems in 19 out of 30 images examined from her dissertation alone.
The fraud techniques were systematic and deliberate. Kawas copied and pasted data from one experiment into another to fabricate results. She digitally altered Western blot bands to make them appear darker or lighter, manipulating evidence of protein expression. She reused the same image to represent different experimental conditions, presenting identical data as if it came from separate experiments. These alterations supported false conclusions about dihexa’s effectiveness in treating brain damage in rats.
The fabricated research became the foundation for the company’s entire business. Two of the falsified papers were cited in a 2013 patent granted to M3 Biotechnology. Three altered papers co-authored by Kawas were referenced in an Athira application for $15 million in funding from the National Institutes of Health. The company’s regulatory filings, investor presentations, and scientific claims all traced back to research that had been systematically manipulated. According to a securities analyst at Stifel, “The scientific hypothesis behind Athira came out of the work Dr. Kawas did” at WSU.
The Federal Cover-Up and Settlement
Evidence suggests Kawas and Athira executives knew about problems with the research years before they became public. In a 2021 internal memo obtained by GeekWire, Kawas admitted she “should have known better” but claimed the errors resulted from poor graduate student training rather than intentional fraud. The memo surfaced only after the scandal forced Athira to disclose the investigation publicly.
The timeline reveals a systematic cover-up. Between January 2016 and June 2021, Athira systematically failed to report allegations of research misconduct to federal agencies despite being legally required to do so under grant agreements with the National Institutes of Health. Concerns about altered images had been raised as early as 2016, but Athira continued using the tainted research to support business operations, regulatory applications, and investor communications. The company went public in September 2020 without disclosing the integrity concerns, raising $238 million from investors who had no knowledge of the foundational research problems.
Federal law requires grant recipients to report research misconduct allegations promptly. Athira violated these requirements for over five years. In January 2025, Athira Pharma agreed to pay $4,068,698 to settle False Claims Act allegations. The Department of Justice found that Athira had received federal grant funding from the National Institutes of Health based on applications that referenced the falsified research. Athira had submitted grant applications to NIH that cited Kawas’ altered papers, including a grant that NIH funded in 2019 with $15 million. Altered images from papers co-authored by Kawas were incorporated into WSU’s patent for dihexa. The fraud contaminated every level of the company’s operations.
The Investor Devastation
When the scandal erupted in October 2021, Athira’s stock crashed from $11 per share to $4.08 in a single trading session, wiping out $261 million in market capitalization overnight. The collapse accelerated over the following months as investors absorbed the implications. Shareholders who participated in the September 2020 IPO at $17 per share suffered losses exceeding 95% as the stock eventually traded below $1. By November 2024, Athira stock traded at approximately $0.42 per share, destroying virtually all shareholder value.
The financial damage extended across the investment landscape. Institutional investors including Perceptive Advisors, RA Capital Management, and Boxer Capital lost tens of millions. Retail investors who bought shares based on the company’s promising Alzheimer’s treatment pipeline saw their investments evaporate. Dozens of Athira employees lost their jobs as the company scaled back operations and eventually wound down most research programs. The company that once employed over 100 people and operated multiple clinical trials became a shell operation.
Clinical trial participants had received experimental treatments based on fraudulent preclinical data, raising serious questions about informed consent and patient safety. The trials tested drugs whose efficacy claims rested on fabricated animal studies. While no patient harm was reported, the ethical violation of administering experimental treatments based on fake research compounded the human cost of the fraud.
Yet Kawas personally faced no criminal prosecution, no SEC enforcement action, no industry ban, and no requirement to return compensation she received while serving as CEO of a company built on her fabricated research. The $4 million settlement was paid by Athira Pharma, not by Kawas individually. She retained her personal wealth accumulated during the fraud. No executive faced personal liability despite overseeing a company that systematically concealed research integrity problems from investors and regulators for years.
The Comeback
Kawas quickly launched Propel Bio Partners LP in March 2022, less than five months after resigning from Athira. The $150 million venture capital fund received backing from the same investors who had lost money in Athira, including prominent Seattle-area venture firms. The fund focuses on early-stage biotechnology investments, allowing Kawas to continue profiting from the same industry she damaged through research fraud. Her ability to raise significant capital immediately after a major scandal demonstrates the absence of meaningful personal consequences for corporate executives whose fraud devastates investors.
Washington State University revoked her PhD following the scandal, but the university had granted her a PhD based on a dissertation riddled with fabricated data. The revocation came only after public pressure and media coverage made inaction untenable. WSU never explained how a dissertation with 19 altered images in 30 examined figures passed doctoral committee review, or why the university’s quality control systems failed to detect systematic fraud.
The SEC never brought enforcement action despite clear securities law violations. Athira made public filings throughout 2020 and 2021 that highlighted Kawas’ research credentials and cited her published papers without disclosing known concerns about data integrity. The company raised $238 million in its IPO while concealing material information about the validity of its foundational research. These omissions violated federal securities disclosure requirements, yet no individual faced charges. The enforcement gap created a blueprint for other executives: build a company on fraud, take it public, collect compensation, and face no personal liability when the scheme collapses.
Several journals eventually retracted Kawas’ papers, but the process took years and occurred only after media coverage forced action. Peer reviewers and journal editors had failed to detect obvious signs of image manipulation that research integrity consultants later found using basic forensic software. The scientific publication system’s failure to catch the fraud enabled Kawas to build a multimillion-dollar company on fabricated research that should never have been published.
Conclusion
Leen Kawas built a biotech company on falsified research, misled federal agencies for years, and presided over a collapse that destroyed hundreds of millions in investor value. The $4 million corporate settlement was paid by the company, not Kawas personally. No criminal charges were filed. Within five months of resigning, Kawas raised $150 million for a new venture capital fund with backing from the same investors who lost money in Athira.
Leave a Reply